AgomAb Therapeutics (NASDAQ:AGMB) CEO Purchases $43,500.00 in Stock

AgomAb Therapeutics NV (NASDAQ:AGMB) CEO Tim Jasper Knotnerus acquired 5,000 shares of the stock in a transaction on Tuesday, October 6th. The shares were purchased at an average price of $8.70 per share, for a total transaction of $43,500.00. Following the completion of the transaction, the chief executive officer owned 21,823 shares in the company, valued at approximately $189,860.10. This represents a 29.72% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website.

Tim Jasper Knotnerus also recently made the following trade(s):

• On Monday, October 5th, Tim Jasper Knotnerus bought 6,000 shares of AgomAb Therapeutics stock. The shares were purchased at an average cost of $8.48 per share, for a total transaction of $50,880.00.

AgomAb Therapeutics Stock Performance

AGMB opened at $9.08 on Friday. The stock has a fifty day moving average of $12.60 and a 200-day moving average of $11.93. AgomAb Therapeutics NV has a 12-month low of $7.97 and a 12-month high of $17.82.

AgomAb Therapeutics (NASDAQ:AGMB) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.46) earnings per share for the quarter. On average, sell-side analysts anticipate that AgomAb Therapeutics NV will post -1.76 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on AGMB. Cantor Fitzgerald assumed coverage on AgomAb Therapeutics in a report on Wednesday, August 19th. They issued an “overweight” rating on the stock. HC Wainwright reaffirmed a “buy” rating on shares of AgomAb Therapeutics in a research report on Wednesday, September 16th. Piper Sandler started coverage on shares of AgomAb Therapeutics in a research note on Tuesday, August 25th. They issued an “overweight” rating and a $60.00 price objective on the stock. Wall Street Zen cut shares of AgomAb Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, September 27th. Finally, B. Riley Financial began coverage on AgomAb Therapeutics in a report on Thursday, July 23rd. They set a “buy” rating and a $34.00 price objective for the company. Seven equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $37.50.

About AgomAb Therapeutics

Agomab Therapeutics N.V. is a clinical-stage biotechnology company developing antibody-based medicines designed to activate biological pathways involved in tissue repair and regeneration. The company focuses on serious diseases in which restoring or rebuilding damaged tissue could provide therapeutic benefit.

Agomab’s lead program, AGMB-129, is an investigational, gut-restricted agonist of fibroblast growth factor receptor 1c (FGFR1c) being developed for inflammatory bowel disease, including Crohn’s disease.